Aprea Therapeutics, Inc. (APRE): R&D Expense
$7.04M
Year ended 2025-12-31
$6.72M
Trailing 12 months to 2026-06-30
-24.6%
3-year compound annual growth
-28.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.04M | -24.8% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $9.36M | +22.8% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $7.63M | -53.5% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $16.40M | -31.4% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $23.90M | -36.9% | 2024-03-26, From 2021-01-01 |
| 2020-12-31 | $37.88M | +80.8% | 2023-03-30, From 2020-01-01 |
| 2019-12-31 | $20.95M | +47.6% | 2022-03-15, From 2019-01-01 |
| 2018-12-31 | $14.19M | +6.0% | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | $13.39M | n/a | 2020-03-27, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $7.04M | -24.8% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $11.71M | -48.9% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $5.07M | -20.7% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $43.0K | -99.5% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $3.19M | -70.7% |
| Cingulate Inc. (CING) | 2025-12-31 | $9.77M | +3.5% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $12.61M | -55.7% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $11.50M | -56.0% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
Compare APRE, RVPH, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗